Safety and Immunogenicity of Novel Respiratory Syncytial Virus (RSV) Vaccines Based on the RSV Viral Proteins F, N and M2-1 Encoded by Simian Adenovirus (PanAd3-RSV) and MVA (MVA-RSV); Protocol for an Open-label, Dose-escalation, Single-centre,...

Overview

Journal BMJ Open

Specialty General Medicine

Date 2015 Oct 30

PMID 26510727

Citations 35

Authors

C A Green

E Scarselli

M Voysey

S Capone

A Vitelli

A Nicosia

R Cortese

A J Thompson

C S Sande

Catherine de Lara

P Klenerman

A J Pollard

Affiliations

Soon will be listed here.

Abstract

Introduction: Respiratory syncytial virus (RSV) infection causes respiratory disease throughout life, with infants and the elderly at risk of severe disease and death. RSV001 is a phase 1 (first-in-man), open-label, dose-escalation, clinical trial of novel genetic viral-vectored vaccine candidates PanAd3-RSV and modified vaccinia virus Ankara (MVA)-RSV. The objective of RSV001 is to characterise the (primary objective) safety and (secondary objective) immunogenicity of these vaccines in healthy younger and older adults.

Methods And Analysis: Heterologous and homologous 'prime'/boost combinations of PanAd3-RSV and single-dose MVA-RSV are evaluated in healthy adults. 40 healthy adults aged 18-50 years test one of four combinations of intramuscular (IM) or intranasal (IN) PanAd3-RSV prime and IM PanAd3 or IM MVA-RSV boost vaccination, starting at a low dose for safety. The following year an additional 30 healthy adults aged 60-75 years test either a single dose of IM MVA-RSV, one of three combinations of IN or IM PanAd3-RSV prime and PanAd3-RSV or MVA-RSV boost vaccination used in younger volunteers, and a non-vaccinated control group. Study participants are self-selected volunteers who satisfy the eligibility criteria and are assigned to study groups by sequential allocation. Safety assessment includes the daily recording of solicited and unsolicited adverse events for 1 week after vaccination, as well as visit (nursing) observations and safety bloods obtained at all scheduled attendances. Laboratory measures of RSV-specific humoral and cellular immune responses after vaccination will address the secondary end points. All study procedures are performed at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, UK.

Ethics And Dissemination: RSV001 has clinical trial authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) and ethics approval from NRES Berkshire (reference 13/SC/0023). All study procedures adhere to International Conference on Harmonisation (ICH) Good Clinical Practice guidelines. The results of the trial are to be published in peer-reviewed journals, conferences and academic forums.

Trial Registration Number: NCT01805921.

Citing Articles

Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.

Ricco M, Abu-Raya B, Icardi G, Spoulou V, Greenberg D, Pecurariu O Vaccines (Basel). 2025; 12(12.

PMID: 39771979 PMC: 11679680. DOI: 10.3390/vaccines12121317.

Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Ricco M, Cascio A, Corrado S, Bottazzoli M, Marchesi F, Gili R Vaccines (Basel). 2024; 12(5).

PMID: 38793751 PMC: 11126042. DOI: 10.3390/vaccines12050500.

All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?.

Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P Vaccines (Basel). 2024; 12(1).

PMID: 38250910 PMC: 10819635. DOI: 10.3390/vaccines12010097.

Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections.

Loo C, Lee W, Zhou Q Pharm Res. 2023; 40(5):1015-1036.

PMID: 37186073 PMC: 10129308. DOI: 10.1007/s11095-023-03520-1.

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.

Green C, McGinley J, Sande C, Capone S, Makvandi-Nejad S, Vitelli A Clin Exp Immunol. 2023; 211(3):269-279.

PMID: 36622786 PMC: 10038321. DOI: 10.1093/cei/uxad003.

References

Hall C, Long C, Schnabel K . Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001; 33(6):792-6. DOI: 10.1086/322657. View

OShea M, Ryan M, Hawksworth A, Alsip B, Gray G . Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. Clin Infect Dis. 2005; 41(3):311-7. DOI: 10.1086/431591. View

Olson M, Varga S . CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol. 2007; 179(8):5415-24. DOI: 10.4049/jimmunol.179.8.5415. View

Glenn G, Smith G, Fries L, Raghunandan R, Lu H, Zhou B . Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2012; 31(3):524-32. DOI: 10.1016/j.vaccine.2012.11.009. View

Yang C, Wang C, Malkin E, Schickli J, Shambaugh C, Zuo F . Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine. 2013; 31(26):2822-7. DOI: 10.1016/j.vaccine.2013.04.006. View

Karron R, Wright P, Belshe R, Thumar B, Casey R, Newman F . Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005; 191(7):1093-104. DOI: 10.1086/427813. View

Szabo S, Gooch K, Bibby M, Vo P, Mitchell I, Bradt P . The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection. Paediatr Respir Rev. 2012; 13 Suppl 2:S1-8. DOI: 10.1016/S1526-0542(12)00095-4. View

Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A . Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012; 4(115):115ra2. PMC: 3627206. DOI: 10.1126/scitranslmed.3002925. View

Deshpande S, Northern V . The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003; 88(12):1065-9. PMC: 1719378. DOI: 10.1136/adc.88.12.1065. View

10.

Rollier C, Reyes-Sandoval A, Cottingham M, Ewer K, Hill A . Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol. 2011; 23(3):377-82. DOI: 10.1016/j.coi.2011.03.006. View

11.

Kim H, Canchola J, BRANDT C, Pyles G, Chanock R, Jensen K . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89(4):422-34. DOI: 10.1093/oxfordjournals.aje.a120955. View

12.

Swadling L, Capone S, Antrobus R, Brown A, Richardson R, Newell E . A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014; 6(261):261ra153. PMC: 4669853. DOI: 10.1126/scitranslmed.3009185. View

13.

Falsey A, Hennessey P, Formica M, Cox C, Walsh E . Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352(17):1749-59. DOI: 10.1056/NEJMoa043951. View

14.

Chin J, MAGOFFIN R, Shearer L, SCHIEBLE J, LENNETTE E . Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969; 89(4):449-63. DOI: 10.1093/oxfordjournals.aje.a120957. View

15.

Renaud C, Xie H, Seo S, Kuypers J, Cent A, Corey L . Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013; 19(8):1220-6. PMC: 3752411. DOI: 10.1016/j.bbmt.2013.05.005. View

16.

Waris M, Tsou C, Erdman D, Day D, Anderson L . Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol. 1997; 71(9):6935-9. PMC: 191977. DOI: 10.1128/JVI.71.9.6935-6939.1997. View

17.

Boyce T, Mellen B, Mitchel Jr E, Wright P, Griffin M . Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000; 137(6):865-70. DOI: 10.1067/mpd.2000.110531. View

18.

. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005; 365(9460):711-22. DOI: 10.1016/S0140-6736(05)17965-3. View

19.

Collins P, Melero J . Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011; 162(1-2):80-99. PMC: 3221877. DOI: 10.1016/j.virusres.2011.09.020. View

20.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View